BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types
The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab
Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS
A first-in-class muscarinic agonist for the treatment of schizophrenia in adults
New analyses, including presentations on mavacamten, apixaban and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases
Application based on the Transcend FL trial in which Breyanzi showed deep and durable responses and a consistent and well-established safety profile
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Dual immunotherapy combination of Opdivo plus Yervoy demonstrated improved survival benefit compared to lenvatinib or sorafenib in this patient population
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
Subscribe To Our Newsletter & Stay Updated
